Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $2.7 million.

  • Theravance Biopharma's Gains from Investment Securities rose 3116.37% to $12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.7 million, marking a year-over-year increase of 720.12%. This contributed to the annual value of $2.7 million for FY2024, which is 6.36% up from last year.
  • As of FY2024, Theravance Biopharma's Gains from Investment Securities stood at $2.7 million, which was up 6.36% from $2.5 million recorded in FY2023.
  • Theravance Biopharma's Gains from Investment Securities' 5-year high stood at $118.0 million during FY2022, with a 5-year trough of $2.5 million in FY2023.
  • Over the past 3 years, Theravance Biopharma's median Gains from Investment Securities value was $2.7 million (recorded in 2024), while the average stood at $41.0 million.
  • Per our database at Business Quant, Theravance Biopharma's Gains from Investment Securities spiked by 1,201.91% in 2022 and then crashed by 97.88% in 2023.
  • Yearly analysis of 5 years shows Theravance Biopharma's Gains from Investment Securities stood at $9.7 million in 2020, then fell by 7.06% to $9.1 million in 2021, then surged by 1,201.91% to $118.0 million in 2022, then plummeted by 97.88% to $2.5 million in 2023, then rose by 6.36% to $2.7 million in 2024.